

## CLAIMS

I claim,

5 1. A method, comprising:  
a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and ii) a formulation comprising an inhibitor that specifically inhibits Type 4 cyclic adenosine monophosphate phosphodiesterases; and  
b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.

10 2. The method of Claim 1, wherein said administering is enteral administration.

3. The method of Claim 2, wherein said enteral administration is oral administration.

4. The method of Claim 1, wherein said administering is parenteral administration.

15 5. The method of Claim 1, wherein said patient is a naive patient.

6. The method of Claim 1, wherein said patient is immunocompromised.

7. The method of Claim 1, wherein said patient is unresponsive to chemotherapy with alkylating agents.

8. A method, comprising:

- a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and ii) a formulation comprising rolipram; and
- b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.

9. The method of Claim 8, wherein said administering is enteral administration.

10. The method of Claim 9, wherein said enteral administration is oral administration.

11. The method of Claim 8, wherein said administering is parenteral administration.

12. The method of Claim 8, wherein said patient is a naive patient.

13. The method of Claim 8, wherein said patient is immunocompromised.

14. The method of Claim 8, wherein said patient is unresponsive to chemotherapy with alkylating agents.